Navigation Links
Paul Keim Appointed to febit's Scientific Advisory Board
Date:4/14/2009

Paul Keim brings deep knowledge in the field of medical microbiology, biodefense and pathogens to febit, the leader in microfluidic microarray DNA analysis technologies

LEXINGTON, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced the recruitment of Paul Keim, Ph.D., for its Scientific Advisory Board. Dr. Keim is Senior Investigator and Director of the Pathogen Genomics Division at TGen (The Translational Genomics Research Institute) in Phoenix, Ariz., and Regents Prof. of Biology at the Northern Arizona University. As an expert in the field of medical microbiology, biosecurity and the genomics of pathogens he brings deep knowledge from these fields to febit.

Dr. Keim's expertise will be particularly helpful in febit's research activities in the field of biosecurity which have resulted from its partnership with In-Q-Tel, the independent strategic investment firm that identifies innovative technology solutions to support the mission of the broader U.S. Intelligence Community. In addition with Dr. Keim's focus on genomic analysis of bacterial pathogens he is an interesting partner in developing special applications in this field for febit's new sequence capture method, HybSelect which enables focused re-sequencing with next-generation sequencers on a high level in output and automation.

Paul Keim will enrich febit's Scientific Advisory Board which consists of leading authorities at the forefront of genetics and genomics research. The SAB members -- from top research institutions and companies -- will provide expert advice on febit's research and development activities associated with its portfolio development.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications -- HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing and protein-coding or non-coding transcriptome profiling -- the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information please visit: www.febit.com

    Contact:

    febit group, Eva Sterzel, eva.sterzel@febit.com, +49 (0)6221 6510-300

    Russo Partners, Martina Schwarzkopf,
    martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292


'/>"/>
SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
3. John Marshall and Kevin McGuinness Appointed to Ellex Board
4. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
5. David Mott Appointed Non Executive Director at Shire
6. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
7. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
8. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
11. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):